Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship, Medical Oncology, Yale University 2006 - 2009
  • Residency, Internal Medicine, Penn State Milton S. Hershey Medical Center 2002 - 2005
  • D.O., New York Institute of Technology, College of Osteopathic Medicine 2001
• Expertise
• 

  Subject Headings

  • Bladder--Cancer--Adjuvant treatment
  • Bladder--Cancer--Chemotherapy
  • Bladder--Cancer--Diagnosis
  • Bladder--Cancer--Immunotherapy--Congresses
  • Bladder--Cancer--Treatment--Congresses
  • Cancer
  • Cancer Vaccines
  • Interleukin-2
  • Kidneys--Cancer--Chemotherapy--Congresses
  • Kidneys--Cancer--Immunotherapy
  • Kidneys--Cancer--Patients--United States
  • Nanoparticles
  • Nanotechnology
• Research
• 

  Selected Grants

  • An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer awarded by Seattle Genetics, Inc 2020 - 2025
  • A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003) awarded by Mirati Therapeutics, Inc. 2019 - 2024
  • Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis awarded by Case Western Reserve University 2020 - 2022
• 

  External Relationships

  • 2bPrecise
  • Bristol Myers Squibb
  • Eisai
  • Genentech
  • Merck & Co. USA (not assoc'd with Merck KGaA)
  • Seattle Genetics
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Nebhan, Caroline A., Alessio Cortellini, Weijie Ma, Teja Ganta, Haocan Song, Fei Ye, Rebecca Irlmeier, et al. “Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.” Jama Oncol, November 4, 2021. https://doi.org/10.1001/jamaoncol.2021.4960.
       Full Text  Link to Item
    • Makrakis, Dimitrios, Rafee Talukder, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim S. Koshkin, et al. “Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.” Bju Int, October 1, 2021. https://doi.org/10.1111/bju.15603.
       Full Text  Link to Item
    • Pal, Sumanta K., Paul H. Frankel, Amir Mortazavi, Matthew Milowsky, Ulka Vaishampayan, Mamta Parikh, Yung Lyou, et al. “Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.” Jama Oncol 7, no. 10 (October 1, 2021): 1536–43. https://doi.org/10.1001/jamaoncol.2021.3441.
       Full Text  Link to Item
    • Shah, Neal R., Brandon Declouette, Kianoush Ansari-Gilani, Mohammad S. Alhomoud, Christopher Hoimes, Nikhil H. Ramaiya, and Ezgi Güler. “High-dose interleukin-2 therapy related adverse events and implications on imaging.” Diagn Interv Radiol 27, no. 5 (September 2021): 684–89. https://doi.org/10.5152/dir.2021.20503.
       Full Text  Link to Item
    • Smith, Daniel A., Ethan Radzinsky, Sree Harasha Tirumani, Ezgi Guler, Andrew Petraszko, Elias Kikano, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.” Ajr Am J Roentgenol 217, no. 3 (September 2021): 613–22. https://doi.org/10.2214/AJR.20.24758.
       Full Text  Link to Item
    • Esagian, Stepan M., Ali Raza Khaki, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Joseph J. Park, et al. “Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.” Bju Int 128, no. 2 (August 2021): 196–205. https://doi.org/10.1111/bju.15324.
       Full Text  Link to Item
    • Galsky, Matthew D., Christopher J. Hoimes, Andrea Necchi, Neal Shore, J Alfred Witjes, Gary Steinberg, Jens Bedke, et al. “Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.” Future Oncol 17, no. 24 (August 2021): 3137–50. https://doi.org/10.2217/fon-2021-0273.
       Full Text  Link to Item
    • Rosenberg, Jonathan E., Karla A. Ballman, Susan Halabi, Pamela J. Atherton, Amir Mortazavi, Christopher Sweeney, Walter M. Stadler, et al. “Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).” J Clin Oncol 39, no. 22 (August 1, 2021): 2486–96. https://doi.org/10.1200/JCO.21.00286.
       Full Text  Link to Item
    • Galsky, Matthew D., Arjun V. Balar, Peter C. Black, Matthew T. Campbell, Gail S. Dykstra, Petros Grivas, Shilpa Gupta, et al. “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.” J Immunother Cancer 9, no. 7 (July 2021). https://doi.org/10.1136/jitc-2021-002552.
       Full Text  Link to Item
    • Khaki, Ali Raza, Ang Li, Leonidas N. Diamantopoulos, Natalie J. Miller, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, et al. “A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.” Eur Urol Oncol 4, no. 3 (June 2021): 464–72. https://doi.org/10.1016/j.euo.2020.12.006.
       Full Text  Link to Item
    • Wang, Xinning, Aditi Shirke, Ethan Walker, Rongcan Sun, Gopolakrishnan Ramamurthy, Jing Wang, Lingpeng Shan, et al. “Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.” Cancers (Basel) 13, no. 3 (January 22, 2021). https://doi.org/10.3390/cancers13030417.
       Full Text  Link to Item
    • Nelson, A. A., R. J. Cronk, E. A. Lemke, A. Szabo, A. R. Khaki, L. N. Diamantopoulos, P. Grivas, et al. “Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.” Bladder Cancer 7, no. 1 (January 1, 2021): 33–42. https://doi.org/10.3233/BLC-200377.
       Full Text
    • Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.
       Full Text  Link to Item
    • Shieh, Alice C., Ezgi Guler, David Pfau, Ethan Radzinsky, Daniel A. Smith, Christopher Hoimes, Nikhil H. Ramaiya, and Sree Harsha Tirumani. “Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.” Abdom Radiol (Ny) 45, no. 10 (October 2020): 3028–35. https://doi.org/10.1007/s00261-019-02334-3.
       Full Text  Link to Item
    • Ansari-Gilani, Kianoush, Sree Harsha Tirumani, Daniel A. Smith, Ariel Nelson, Asrar Alahmadi, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.” Emerg Radiol 27, no. 4 (August 2020): 455–60. https://doi.org/10.1007/s10140-020-01765-6.
       Full Text  Link to Item
    • Miller, Natalie J., Ali Raza Khaki, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, Neeraj Agarwal, Rafael Morales-Barrera, et al. “Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.” J Urol 204, no. 1 (July 2020): 63–70. https://doi.org/10.1097/JU.0000000000000761.
       Full Text  Link to Item
    • Khaki, Ali Raza, Ang Li, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, John Esther, Rafael Morales-Barrera, et al. “Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.” Cancer 126, no. 6 (March 15, 2020): 1208–16. https://doi.org/10.1002/cncr.32645.
       Full Text  Link to Item
    • Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, et al. “Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 3 (March 2020): 329–54. https://doi.org/10.6004/jnccn.2020.0011.
       Full Text  Link to Item
    • Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J. Hoimes, Ulka Vaishampayan, et al. “Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.” J Clin Oncol 38, no. 5 (February 10, 2020): 395–405. https://doi.org/10.1200/JCO.19.01638.
       Full Text  Link to Item
    • “Novel MYC-Targeting Drug Is Effective in Mouse Prostate Cancer Models.” Cancer Discov 10, no. 1 (January 2020): 15. https://doi.org/10.1158/2159-8290.CD-RW2019-167.
       Full Text  Link to Item
    • Atukorale, Prabhani U., Shruti P. Raghunathan, Vanitha Raguveer, Taylor J. Moon, Carolyn Zheng, Peter A. Bielecki, Michelle L. Wiese, et al. “Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.” Cancer Res 79, no. 20 (October 15, 2019): 5394–5406. https://doi.org/10.1158/0008-5472.CAN-19-0381.
       Full Text  Link to Item
    • Sadeghi, Sarmad, Susan G. Groshen, Denice D. Tsao-Wei, Rahul Parikh, Amir Mortazavi, Tanya B. Dorff, Cheryl Kefauver, et al. “Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).” J Clin Oncol 37, no. 29 (October 10, 2019): 2682–88. https://doi.org/10.1200/JCO.19.00861.
       Full Text  Link to Item
    • Pal, Sumanta K., Andres Forero-Torres, John A. Thompson, John C. Morris, Saurabh Chhabra, Christopher J. Hoimes, Nicholas J. Vogelzang, et al. “A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.” Cancer 125, no. 7 (April 1, 2019): 1124–32. https://doi.org/10.1002/cncr.31912.
       Full Text  Link to Item
    • Thompson, John A., Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, et al. “Management of Immunotherapy-Related Toxicities, Version 1.2019.” J Natl Compr Canc Netw 17, no. 3 (March 1, 2019): 255–89. https://doi.org/10.6004/jnccn.2019.0013.
       Full Text  Link to Item
    • Beltran, Himisha, Clara Oromendia, Daniel C. Danila, Bruce Montgomery, Christopher Hoimes, Russell Z. Szmulewitz, Ulka Vaishampayan, et al. “A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.” Clin Cancer Res 25, no. 1 (January 1, 2019): 43–51. https://doi.org/10.1158/1078-0432.CCR-18-1912.
       Full Text  Link to Item
    • Le Tourneau, Christophe, Christopher Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, et al. “Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.” J Immunother Cancer 6, no. 1 (October 22, 2018): 111. https://doi.org/10.1186/s40425-018-0424-9.
       Full Text  Open Access Copy  Link to Item
    • Hoimes, C. J., C. Albany, J. Hoffman-Censits, M. T. Fleming, E. Trabulsi, J. Picus, C. Cary, et al. “A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC).” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii726. https://doi.org/10.1093/annonc/mdy424.039.
       Full Text
    • Long, G. V., M. Milhem, A. Amin, C. J. Hoimes, T. Medina, R. M. Conry, C. Lao, et al. “Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii736. https://doi.org/10.1093/annonc/mdy424.055.
       Full Text
    • Ribas, A., I. Mehmi, T. Medina, C. Lao, S. Kummar, A. Amin, S. Deva, et al. “Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy.” Ann Oncol 29 Suppl 8 (October 2018): viii451–52. https://doi.org/10.1093/annonc/mdy289.021.
       Full Text  Link to Item
    • Tzeng, Alice, C Marcela Diaz-Montero, Patricia A. Rayman, Jin S. Kim, Paul G. Pavicic, James H. Finke, Pedro C. Barata, et al. “Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.” Target Oncol 13, no. 5 (October 2018): 599–609. https://doi.org/10.1007/s11523-018-0595-9.
       Full Text  Link to Item
    • Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, et al. “NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.” J Natl Compr Canc Netw 16, no. 9 (September 2018): 1041–53. https://doi.org/10.6004/jnccn.2018.0072.
       Full Text  Link to Item
    • Kang, Kylie H., William Grubb, Komal Sawlani, Michael K. Gibson, Christopher J. Hoimes, Lisa R. Rogers, Pierre Lavertu, and Min Yao. “Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.” Am J Otolaryngol 39, no. 5 (September 2018): 642–45. https://doi.org/10.1016/j.amjoto.2018.06.003.
       Full Text  Link to Item
    • Ornstein, Moshe C., Claudia Marcela Diaz-Montero, Patricia Rayman, Paul Elson, Samuel Haywood, James H. Finke, Jin S. Kim, et al. “Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.” Urol Oncol 36, no. 9 (September 2018): 405–12. https://doi.org/10.1016/j.urolonc.2018.02.018.
       Full Text  Link to Item
    • Agarwal, Neeraj, Sumanta K. Pal, Andrew W. Hahn, Roberto H. Nussenzveig, Gregory R. Pond, Sumati V. Gupta, Jue Wang, et al. “Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.” Cancer 124, no. 10 (May 15, 2018): 2115–24. https://doi.org/10.1002/cncr.31314.
       Full Text  Link to Item
    • Rosenberg, Jonathan E., Noah M. Hahn, Meredith M. Regan, Lillian Werner, Ajjai Alva, Saby George, Joel Picus, et al. “Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).” Br J Cancer 118, no. 11 (May 2018): 1434–41. https://doi.org/10.1038/s41416-018-0087-9.
       Full Text  Link to Item
    • Spiess, Philippe E., Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, et al. “Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 10 (October 2017): 1240–67. https://doi.org/10.6004/jnccn.2017.0156.
       Full Text  Link to Item
    • Powles, Thomas, Peter H. O’Donnell, Christophe Massard, Hendrik-Tobias Arkenau, Terence W. Friedlander, Christopher J. Hoimes, Jae Lyun Lee, et al. “Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.” Jama Oncol 3, no. 9 (September 14, 2017): e172411. https://doi.org/10.1001/jamaoncol.2017.2411.
       Full Text  Link to Item
    • Beltran, H., D. Danila, B. Montgomery, R. Szmulewitz, U. Vaishampayan, A. Armstrong, M. Stein, et al. “A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).” Annals of Oncology 27 (October 1, 2016): vi565. https://doi.org/10.1093/annonc/mdw435.21.
       Full Text
    • Clark, Peter E., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, et al. “NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.” J Natl Compr Canc Netw 14, no. 10 (October 2016): 1213–24. https://doi.org/10.6004/jnccn.2016.0131.
       Full Text  Link to Item
    • Antunes, Jacob, Satish Viswanath, Mirabela Rusu, Laia Valls, Christopher Hoimes, Norbert Avril, and Anant Madabhushi. “Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study.” Transl Oncol 9, no. 2 (April 2016): 155–62. https://doi.org/10.1016/j.tranon.2016.01.008.
       Full Text  Link to Item
    • Kiechle, Jonathan E., Robert Abouassaly, Cary P. Gross, Shan Dong, Edward E. Cherullo, Hui Zhu, Quoc-Dien Trinh, et al. “Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort.” Urology 90 (April 2016): 69–74. https://doi.org/10.1016/j.urology.2015.10.035.
       Full Text  Link to Item
    • Hoimes, Christopher J., and Anant Madabhushi. “Editorial Comment.” Urology 88 (February 2016): 132–33. https://doi.org/10.1016/j.urology.2015.09.043.
       Full Text  Link to Item
    • Oliveira, Guilherme H., Sadeer G. Al-Kindi, Christopher Hoimes, and Soon J. Park. “Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of >500 Patients.” Circulation 132, no. 25 (December 22, 2015): 2395–2402. https://doi.org/10.1161/CIRCULATIONAHA.115.016418.
       Full Text  Link to Item
    • Peiris, Pubudu M., Aaron Abramowski, James Mcginnity, Elizabeth Doolittle, Randall Toy, Ramamurthy Gopalakrishnan, Shruti Shah, et al. “Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.” Cancer Res 75, no. 7 (April 1, 2015): 1356–65. https://doi.org/10.1158/0008-5472.CAN-14-1540.
       Full Text  Link to Item
    • Toy, Randall, Lisa Bauer, Christopher Hoimes, Ketan B. Ghaghada, and Efstathios Karathanasis. “Targeted nanotechnology for cancer imaging.” Adv Drug Deliv Rev 76 (September 30, 2014): 79–97. https://doi.org/10.1016/j.addr.2014.08.002.
       Full Text  Link to Item
    • Deng, Yang, Jennifer K. Saucier-Sawyer, Christopher J. Hoimes, Junwei Zhang, Young-Eun Seo, Jillian W. Andrejecsk, and W Mark Saltzman. “The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles.” Biomaterials 35, no. 24 (August 2014): 6595–6602. https://doi.org/10.1016/j.biomaterials.2014.04.038.
       Full Text  Link to Item
    • Valls, Laia, Christopher Hoimes, Andrew Sher, Lingzhi Hu, Zhenghong Lee, Raymond Muzic, and Norbert Avril. “Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.” Semin Roentgenol 49, no. 3 (July 2014): 238–41. https://doi.org/10.1053/j.ro.2014.09.001.
       Full Text  Link to Item
    • Martin, Darryl T., Christopher J. Hoimes, Hristos Z. Kaimakliotis, Christopher J. Cheng, Ke Zhang, Jingchun Liu, Marcia A. Wheeler, et al. “Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.” Nanomedicine 9, no. 8 (November 2013): 1124–34. https://doi.org/10.1016/j.nano.2013.05.017.
       Full Text  Link to Item
    • Fields, Rachel J., Christopher J. Cheng, Elias Quijano, Caroline Weller, Nina Kristofik, Nha Duong, Christopher Hoimes, Marie E. Egan, and W Mark Saltzman. “Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery.” J Control Release 164, no. 1 (November 28, 2012): 41–48. https://doi.org/10.1016/j.jconrel.2012.09.020.
       Full Text  Link to Item
    • Hoimes, Christopher J., and W Kevin Kelly. “Redefining hormone resistance in prostate cancer.” Ther Adv Med Oncol 2, no. 2 (March 1, 2010): 107–23. https://doi.org/10.1177/1758834009356433.
       Full Text  Link to Item
    • Hoimes, Christopher J., Megan K. Selbst, Nelofar Q. Shafi, Michal G. Rose, and Manuel F. Rosado. “Hodgkin's lymphoma of the breast.” J Clin Oncol 28, no. 2 (January 10, 2010): e11–13. https://doi.org/10.1200/JCO.2009.23.1613.
       Full Text  Link to Item
    • Strimpakos, A. S., C. Hoimes, K. N. Syrigos, and M. W. Saif. “Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?” Current Pharmacogenomics and Personalized Medicine 8, no. 1 (January 1, 2010): 73–88. https://doi.org/10.2174/1875692111008010073.
       Full Text
    • Merl, My, Cj Hoimes, T. Pham, and M Wasif Saif. “Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).” Expert Opin Investig Drugs 18, no. 9 (September 2009): 1257–64. https://doi.org/10.1517/13543780903136724.
       Full Text  Link to Item
    • Hoimes, Christopher J., Matthew T. Moyer, and Muhammad Wasif Saif. “Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.” Jop 10, no. 4 (July 6, 2009): 352–56.
       Link to Item
    • Hoimes, Christopher J., Alexios S. Strimpakos, and Muhammad Wasif Saif. “Therapeutic tools in pancreatic cancer.” Jop 10, no. 2 (March 9, 2009): 118–22.
       Link to Item
    • Strimpakos, Alexios S., Christopher Hoimes, and Muhammad Wasif Saif. “Pancreatic cancer: translating lessons from mouse models.” Jop 10, no. 2 (March 9, 2009): 98–103.
       Link to Item
    • Hoimes, Christopher J., and Wm Kevin Kelly. “TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality.” Update Cancer Ther 3, no. 4 (2009): 157–59. https://doi.org/10.1016/j.uct.2009.03.001.
       Full Text  Link to Item
    • Dodson, Cassidy, Daniel A. Smith, Tyler J. Richards, Robert R. Devita, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Systemic Therapies for Melanoma Brain Metastases: A Primer for Radiologists.” J Comput Assist Tomogr 44, no. 3 (n.d.): 346–55. https://doi.org/10.1097/RCT.0000000000001006.
       Full Text  Link to Item
    • Liput, Joseph, Ezgi Guler, Daniel A. Smith, Sree Harsha Tirumani, Christopher Hoimes, Paolo F. Caimi, and Nikhil H. Ramaiya. “Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.” J Comput Assist Tomogr 44, no. 4 (n.d.): 619–26. https://doi.org/10.1097/RCT.0000000000001043.
       Full Text  Link to Item

  • Book Sections

    • Hoimes, C. J. “Antimicrotubule agents.” In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, 288–97, 2018.
    • Hoimes, C. J., and L. N. Harris. “Antimicrotubule agents.” In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology: Tenth Edition, 2015.
    • Hoimes, C., G. Gibney, and W. K. Kelly. “Systemic therapy for advanced prostate cancer.” In Essentials and Updates in Urologic Oncology (2 Volume Set), 155–92, 2012.

  • Conference Papers

    • Antonarakis, E. S., J. M. Piulats, M. Gross-Goupil, J. C. Goh, U. N. Vaishampayan, R. De Wit, T. V. Alanko, et al. “611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study.” In Annals of Oncology, 32:S651–52. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1124.
       Full Text
    • Graff, J. N., S. Tagawa, C. Hoimes, W. Gerritsen, U. N. Vaishampayan, T. Elliott, C. Hwang, et al. “61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199.” In Annals of Oncology, 32:S383–S383. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.341.
       Full Text
    • Esagian, Stepan M., Ali Raza Khaki, Lucia Carril-Ajuria, Joseph J. Park, Mehmet Asim Bilen, Tyler Francis Stewart, Victor Sacristan Santos, et al. “Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.” In Journal of Clinical Oncology, 39:406–406. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.406.
       Full Text
    • Rosenberg, J. E., T. W. Flaig, T. W. Friedlander, M. I. Milowsky, S. Srinivas, D. P. Petrylak, J. R. Merchan, et al. “First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC).” In Swiss Medical Weekly, 26S-27S, 2020.
       Link to Item
    • Vaishampayan, U. N., T. Elliott, A. G. Omlin, J. N. Graff, C. J. Hoimes, S. T. Tagawa, C. Hwang, et al. “227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199.” In Annals of Oncology, 31:S1330–S1330. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.10.447.
       Full Text
    • Omlin, A. G., J. N. Graff, C. J. Hoimes, S. T. Tagawa, C. Hwang, D. Kilari, A. J. Ten Tije, et al. “623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update.” In Annals of Oncology, 31:S514–15. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.882.
       Full Text
    • Hoimes, Christopher J., Julie N. Graff, Scott T. Tagawa, Clara Hwang, Deepak Kilari, A. J. Ten Tije, Aurelius Omlin, et al. “KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Hoimes, Christopher J., Nabil Adra, Mark T. Fleming, Hristos Z. Kaimakliotis, Joel Picus, Zachary L. Smith, Radhika Walling, et al. “Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Kaimakliotis, Hristos Z., Nabil Adra, William Kevin Kelly, Edouard John Trabulsi, Richard C. Lauer, Joel Picus, Zachary L. Smith, et al. “Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Mar, Nataliya, Terence W. Friedlander, Christopher J. Hoimes, Thomas W. Flaig, Mehmet Asim Bilen, Arjun Vasant Balar, Elizabeth Henry, et al. “Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Rosenberg, Jonathan E., Thomas W. Flaig, Terence W. Friedlander, Matthew I. Milowsky, Sandy Srinivas, Daniel Peter Petrylak, Jaime R. Merchan, et al. “Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Ribas, Antoni, Mohammed M. Milhem, Christopher J. Hoimes, Asim Amin, Inderjit Mehmi, Christopher D. Lao, Robert Martin Conry, et al. “Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” In Journal of Clinical Oncology, 36:9513–9513. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.9513.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.